Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide plus abiraterone acetate and prednisone/prednisolone versus placebo plus abiraterone acetate and prednisone/prednisolone in chemotherapy-naive metastatic castration-resistant prostate cancer
2014-001718-25Phase 3Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Apalutamide + AAP with Placebo + AAP (2 arms). Primary endpoint: Radiographic progression-free survival. Status: unknown.
02
Drugs
apalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2014-001718-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001718-25.